TriLink secures new China patent for CleanCap technology
TriLink BioTechnologies has been granted a new patent by China’s patent office, expanding protection for its CleanCap technology. The patent covers compositions and methods for synthesizing 5'-capped RNAs and extends coverage beyond previous method claims to include the molecules at the heart of mRNA medicines.
What changed with the patent grant
The company received patent ZL202511246658.5 from the China National Intellectual Property Administration. The patent broadens protection for CleanCap components, Issuing a second granted CleanCap patent in China within months, and extends to the actual cap analogs and some mRNA compositions used in medicines.
Key facts you should know
CleanCap is a technology used in mRNA production to create a chemical cap at the 5' end of RNA, which helps mRNA medicines work more reliably in the body. The new patent covers both the cap-analog compounds themselves and certain pharmaceutical compositions that use these capped RNAs. The patent is issued by CNIPA, China’s national patent office. This adds to TriLink’s existing intellectual property footprint in China and may influence licensing and competitiveness in the region.
Who is affected
Biotech and pharmaceutical developers using capped RNA technologies or CleanCap in China may encounter stronger IP protection from TriLink. Competitors could seek licenses or modify processes to avoid covered methods, while TriLink may have more leverage in licensing deals within China.
Practical next steps
For researchers or companies: review whether your RNA-capping processes rely on CleanCap in China, and assess potential IP risk or licensing needs. For investors: monitor TriLink’s licensing activity and any related partnerships in China. For others: stay updated on any official CNIPA notices that expand or adjust the scope of the patent.
Limits and questions to consider
The article’s source is a trade press release and a market news site. Details about the patent’s exact claims and enforceability in China may require direct CNIPA records or TriLink’s official filings for full interpretation. No local implications beyond patent scope are stated in the source provided.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- investingnews.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.